Alkermes plc (ALKS)
| Previous close | 24.54 |
| Open | 23.85 |
| Bid | 20.51 x 100 |
| Ask | 27.47 x 100 |
| Day's range | 23.26 - 24.25 |
| 52-week range | 22.01 - 33.71 |
| Volume | |
| Avg. volume | 2,033,798 |
| Market cap | 4.087B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 7.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Alkermes plc Reports First Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024.
- PR Newswire
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant deficiency
- PR Newswire
Alkermes to Report First Quarter Financial Results on May 1, 2024
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results.
